RxDoctor Payments Data

Michael Weymers, NP

Family · Columbia, SCNPI 1174184519

Payments from drug & device makers

$1,176in general payments, 2019–2025

Across 68 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$224
  • AbbVie$111
  • Bayer$101
  • Amgen$96
  • Novo Nordisk$96
  • Pfizer$94
  • plus $455 from 14 others

What the payments were for

  • Food & beverage$1,176100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,176 in reported general payments places this provider in the 70th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$96,374
Medicare patients
188
Services billed
1,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$173,085
JardianceEmpagliflozin58$78,787
MounjaroTirzepatide43$57,117
TrulicityDulaglutide14$24,839
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$22,599
EliquisApixaban21$18,439
XareltoRivaroxaban14$17,601
JanuviaSitagliptin Phosphate11$16,198
Tresiba Flextouch U-100Insulin Degludec17$13,228
Repatha SureclickEvolocumab19$10,267
MyrbetriqMirabegron11$5,718
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$5,071
Novolog FlexpenInsulin Aspart19$4,028
Atorvastatin Calcium277$2,749
Nano 2nd Gen Pen NeedlePen Needle, Diabetic21$2,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$96$173,08590 claims
Lilly USA, LLCMounjaro, Trulicity$224$81,95657 claims
Boehringer IngelheimJardiance$61$78,78758 claims
PfizerEliquis$94$18,43921 claims
Johnson & JohnsonXarelto$13$17,60114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →